Atara Biotherapeutics
ATRA
134 hedge funds and large institutions have $778M invested in Atara Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 47 increasing their positions, 41 reducing their positions, and 26 closing their positions.
471% more call options, than puts
Call options by funds: $2.32M | Put options by funds: $407K
32% more capital inflows, than outflows
Capital inflows: $44.8M | Capital outflows: $34.1M
15% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 41
1.71% more ownership
Funds ownership: 105.15% → 106.86% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 144 → 134 (-10)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wasatch Advisors
Salt Lake City,
Utah
|
+$8.51M |
| 2 |
BlackRock
New York
|
+$6.3M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$4.86M |
| 4 |
JP Morgan Chase
New York
|
+$4.38M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$4.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.57M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$3.55M |
| 3 |
Millennium Management
New York
|
-$2.49M |
| 4 |
Renaissance Technologies
New York
|
-$2.25M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.8M |
ATRA Hedge Fund Activity: Q2 2022 in Review
134 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2022, worth a combined $778M — down 15% from $910M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ATRA and 19 opened new positions — a net loss of 7 holders — while 41 trimmed existing stakes and 47 added.
The largest buyer was Wasatch Advisors, adding an estimated $8.51M. The largest seller was Goldman Sachs, cutting an estimated $4.57M.
- 134 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2022, down from 144 in Q1 2022.
- Funds reported $778M of Atara Biotherapeutics stock for Q2 2022, down 15% quarter-over-quarter.
- 19 funds opened new Atara Biotherapeutics positions in Q2 2022 and 26 closed out, a net change of -7 holders.
- The largest Atara Biotherapeutics buyer in Q2 2022 was Wasatch Advisors, an estimated $8.51M added.
- The largest Atara Biotherapeutics seller in Q2 2022 was Goldman Sachs, an estimated $4.57M sold.
Based on aggregated 13F filings for Q2 2022.